Onatasertib

N/A

Report date: 2024/11/22 20:00:28
NME

Base Information

Drug NameOnatasertib
Drug Alias NameOnatasertib - CelgeneATG-008CC-223
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesCelgene Corp
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAntengene Corp LtdAntengene Corporation Co Ltd
Inactive CompaniesHalo Pharmaceutical IncCelgene CorpAntengene Therapeutics Ltd +[5] 
Active IndicationsUterine Cervical NeoplasmsLung Neoplasms
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungBreast Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksN/A